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Distribution of FK 506 in Plasma Lipoproteins in Transplant Patients 
V. Warty, R. Venkataramanan, P. Zendehrouh, T. McKaveney, J. Chao, S. Todo, and T. Starzl 
FK 506, a powerful. new immunosuppressive agent, is 
currently undergoing clinical trials in transplant pa-
tients. Like cyclosporine (CyA). FK 506 suppresses inter-
leukin-2 production and receptor expression on T cells. 1.2 
Additionally, both FK 506 and CyA are highly lipophilic. 3 
CyA is mainly transported by lipoproteins in plasma.4 The 
objective of the present study is to characterize the distri-
bution of FK 506 in various plasma components. 
MATERIALS AND METHODS 
Materials 
FK 506 powder drug. FK 5{)6..peroxidase conjugate (FK-PODl. 
and anti-FK 506 monoclonal antibody was a gift from Fujisawa 
Pharmaceutical Co .. Ltd. Osaka. Japan. Goat anti-mouse poly-
clonal antibody was obtained from Atlantic Antibodies (Stillwa-
ter. MN). All necessary reagents were prepared with analytical 
grade chemicals. Sample extractions were performed using the 
Sep-Pak Cartridge Column (Waters, Milford, MA) method with an 
ALL TECH Manifold Assembly. Extracted samples were plated 
on a Linbro EIA-II Plus 96-well microtiter plate and absorbance 
readings were made using a Titertek Multiskan Plus microtiter 
plate reader (Flow Laboratories, McLean, V A) at 492 nm. Ultra-
centrifugations were performed in a Beckman LS-SO ultracentri-
fuge using a Ti80 rotor. 
Methods 
The distribution of FK 506 in plasma lipoproteins in vivo was 
studied in 13 transplant patients receiving an oral dose of FK 506 
twice a day. Blood specimens, representing trough levels in these 
individuals, were warmed to 37°C for I hour, the erythrocytes 
were then separated from the plasma by centrifugation for 15 
minutes at 1500 g and 37"C. The plasma samples from each patient 
were pooled and the lipoproteins were separated by ultracentrif-
ugation using a sequential density gradient. Plasma very 101.1.'-
density lipoprotein ([VLDLJ 1.006-1.019 glmL), low-density lipo-
protein ([LDL) 1.019-J.()63 glmL), and high-density lipoprotein 
«HDLJ 1.063-1.21 glmLl were separated by standard differential 
ultracentrifugation techniques using appropriate density gradi-
entsK~ The remaining fraction was termed lipoprotein deficient 
serum (LPDSl. The distribution of FK 506 among each fraction 
was determined using a two-step enzyme-linked immunoabsorp-
tion assay (ELISA) that utilizes a double antibody reaction.6 A 
standard curve was produced by the addition of FK 506, in 
methanol. to blood bank plasma to give final concentrations of 0, 
0.1.0.5. 1.0. 2.0, 5.0. and 10.0 ngimL. The standards and patient 
samples were extracted using Sep-Pak columns. The bound FK 
506 was eluted with methanol and then evaporated to dryness 
under nitrogen. The dried samples were then analyzed by the 
method described by Tamura et al.6 Plasma lipoprotein choles-
terol in each of the patient lipoprotein fractions was measured by 
the Cobas Bio Chemical Analyzer (Roche. Nutley, NJ). 
RESULTS 
The distribution of FK 506 (Table I) in plasma VLDL was 
II :!: 3%; LDL. 3 :!: 3%; HDL. 21 :!: 8%; and the remaining 
in lipoprotein deficient (LPDS) fraction. 64 :!: 8%. The 
plasma lipoprotein fractions were also analyzed for the 
relative percent distribution of cholesterol (Table 2). 
VLDL contained 12 :!: 7%; LDL, 57 :!: 8%; HDL, 27 :!: 
10%; and LPDS. 4 :!: 2%. The FK 506 plasma concentra-
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Table 1. Distribution of FK 506 In Plasma Upoprotelns In Transplant Patients 
FK 506 (nglml) Percentage of Distribution of Plasma Concentration 
Patien1 No. Plasma VlOl LDl HDl LPDS 
1 12.8 9 7 21 63 
2 19.0 12 9 19 60 
3 1.1 10 7 26 57 
4 2.1 9 3 29 59 
5 1.4 9 5 30 56 
6 7.9 15 5 20 60 
7 0.4 8 NO 26 66 
8 1.8 9 NO 28 61 
9 0.5 11 NO 15 72 
10 0.3 8 NO 20 72 
11 1.0 16 NO 21 62 
12 0.7 11 NO NO 84 
13 1.9 11 5 19 65 
Mean = SO 11 = 3 3=3 21 = 8 64 = 8 
Abbreviation: NO. nondeIedIbIe. 
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Table 2. Distribution of Cholesterol In Plasma Lipoproteins In Transplant Patients 
--
Cholesterol (mgllt.) 
PII*1I No Plasma VLDl 
-
103 13 1 
2 127 18 
3 117 11 
4 128 7 
5 99 11 
6 107 10 
7 122 8 
8 150 14 
9 112 10 
10 133 5 
11 162 28 
12 169 22 
13 76 2 
Mean ~ SO 12 ~ 7 
tion ranged from 0.25 to 12.8 ngimL. However, there was 
no systemic change in the percent distribution of FK 506 
into various plasma components indicating linear uptake 
over this concentration range. 
DISCUSSION 
Using conventional differential ultracentrifugation meth-
ods with density gradients. we separated the plasma lipo-
proteins from the pooled serum of 13 transplant patients. 
The plasma lipoprotein fractions were then analyzed for 
the average percent distribution of both FK 506 and 
cholesterol. The distribution of FK 506 was highest in the 
LPDS fraction of the plasma (Fig I). In contrast. the 
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Fig 1. Average percentage of distribution of FK 506, CyA, and 
cholesterol. 
Percentage of 0istrb..4I0n of Plasma Concentration 
LDL HDL LPOS 
62 . 22 3 
67 13 2 
51 34 4 
58 32 3 
62 24 3 
73 14 3 
44 45 3 
55 29 2 
50 35 5 
51 41 3 
48 22 2 
52 18 B 
63 30 5 
57 ~ B 27 ~ 10 4~O 
average percent dist:-;bution of cholesterol was found to be 
lowest in this fracti..-n (Fig I). This finding is particularly 
interesting in view o-f the belief that FK 506 is similar to 
CyA in its lipophilic ;:>roperties as well as its mechanism of 
immunosuppressive activity. The majority of plasma CyA 
is associated with LDL and HDL where the average 
percent distribution of cholesterol is highest (Fig 1).4 
These observations show that FK 506 and CyA have 
significantly differen: distributions in plasma; additionally. 
this suggests that the mechanism of transport in plasma 
may be different for the two compounds. We propose that 
plasma FK 506 is rn..llnly associated with plasma proteins, 
such as albumin and or alpha-I acid glycoprotein (AAG). 
These results indJo.;ate that changes in lipoprotein con-
centrations in transplant patients are not likely to alter FK 
506 distribution in plasma. while those of albumin and 
AAG are more likel~ to change the extent of binding of FK 
506 to plasma protems. 
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